SCOTUS won’t resuscitate Amarin’s Vascepa patents

Amarin has failed to persuade the US Supreme Court to consider reviving six patents on the heart medicine Vascepa (icosapent ethyl), allowing generic drugmakers Hikma Pharmaceuticals and Dr. Reddy’s Laboratories to roll out copycat products.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Amarin appeals ‘skinny label’ loss

23 November 2022 Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.

Americas

SCOTUS asks for SG’s view on enablement in antibody dispute

19 April 2022 The US Supreme Court has asked the Solicitor General to wade in on a case centring on the legal concept of enablement that is the crux of an antibody patent dispute between Amgen and Sanofi.

Big Pharma

Amarin petitions Supreme Court to revive Vascepa patents

18 February 2021 Irish pharmaceutical company Amarin has petitioned the Supreme Court to revive its patents on its heart medication Vascepa.